Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase

Anca Bulgaru; Sridhar Mani; Sanjay Goel; Román Pérez-Soler

doi:10.1586/14737140.3.3.269

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor prognosis in several human malignancies. In addition, cancers overexpressing EGFR respond poorly to both chemotherapy and radiation therapy. Therefore, EGFR is a viable target for cancer therapy. This review will address how EGFR blockade modulates signal transduction, leading to alterations in the cell cycle progression with secondary inhibition of proliferation and differentiation of cancer cells. As a prototypical example, erlotinib (Tarceva), a reversible EGFR tyrosine kinase inhibitor will be discussed. This drug has demonstrated promising antitumor activity in Phase II trials in several solid tumors and definitive Phase III studies to demonstrate clinical benefit have completed accrual.

Keywords

ErlotinibMedicineEpidermal growth factor receptorCancer researchEGFR inhibitorsTyrosine kinaseTyrosine-kinase inhibitorGefitinibPharmacologyCancerDrugReceptorInternal medicine

Affiliated Institutions

Related Publications

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao , Vincent A. Miller , Maureen F. Zakowski +12 more

Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib ...

2004 Proceedings of the National Academy o... 4316 citations

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez , Pasi A. Jänne , Jeffrey C. Lee +14 more

Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGF...

2004 Science 9327 citations

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

James Bean , Gregory J. Riely , Marissa N. Balak +4 more

Abstract Purpose: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to ...

2008 Clinical Cancer Research 276 citations

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Gottfried E. Konecny , Mark D. Pegram , Natarajan Venkatesan +12 more

Abstract Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of ...

2006 Cancer Research 900 citations

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

Jennifer L. Stamos , Mark X. Sliwkowski , Charles Eigenbrot

The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2...

2002 Journal of Biological Chemistry 1443 citations

Publication Info

Year: 2003
Type: review
Volume: 3
Issue: 3
Pages: 269-279
Citations: 47
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Anca Bulgaru, 
                                
                                    Sridhar Mani, 
                                
                                    Sanjay Goel
                                
                                et al.
                            
                            (2003). 
                            Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase. 
                            Expert Review of Anticancer Therapy
                            , 3
                            (3)
                            , 269-279.
                            https://doi.org/10.1586/14737140.3.3.269
                        

Identifiers

DOI: 10.1586/14737140.3.3.269